HRSA received 59 comments on training and care delivery models for safely administering potential FDA-approved psychedelic therapies in ambulatory settings.

The U.S. Health Resources and Services Administration issued its request for information on 14 July, with submissions closing on 13 August. Responses covered workforce training, delivery through community and rural clinics, and technology-enabled scalability, and came from drug developers, care providers, advocacy groups, professional associations and others.